Agilent Technologies, Inc.
AHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeAgilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. At a $41.41B market cap, Agilent Technologies, Inc. ranks as a large-cap company within healthcare. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Market Cap
$41.41B
Beta
1.24
P/E (TTM)
28.96
P/E (Fwd)
21.71
EPS (TTM)
$5.07
EPS (Fwd)
$6.76
ROE
21.0%
ROA
8.6%
Cash
$1.76B
Total Debt
$4.15B
Free CF
$1.06B
52W Change
21.5%
Annual Financials
Cash vs Debt
Where A stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, A finished 18.77% above its 150-day moving average ($127.47) and 15.42% above its 200-day moving average ($131.17). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is A overbought or oversold?
At the September 3, 2026 close, A's RSI(14) was 53.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, A has $1.76B in cash with $4.15B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $1.06B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 21.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $6.85B (2022) to $6.95B (2025).
As with any equity investment, A carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Agilent Technologies, Inc.'s trajectory.